{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T03:15:11Z","timestamp":1780456511175,"version":"3.54.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,11,5]],"date-time":"2009-11-05T00:00:00Z","timestamp":1257379200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1007\/s00535-009-0149-0","type":"journal-article","created":{"date-parts":[[2009,11,4]],"date-time":"2009-11-04T08:12:13Z","timestamp":1257322333000},"page":"326-334","source":"Crossref","is-referenced-by-count":11,"title":["Clinical significance of alanine aminotransferase levels and the effect of ursodeoxycholic acid in hemodialysis patients with chronic hepatitis C"],"prefix":"10.1007","volume":"45","author":[{"given":"Chika","family":"Nishida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Uto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Oketani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Nosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manei","family":"Oku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Sogabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Moriuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Ido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Tsubouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,11,5]]},"reference":[{"key":"149_CR1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0272-6386(03)00828-X","volume":"42","author":"CM Meyers","year":"2003","unstructured":"Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle GH. Hepatitis C and renal disease: an update. Am J Kidney Dis. 2003;42:631\u201357.","journal-title":"Am J Kidney Dis"},{"key":"149_CR2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1034\/j.1600-6143.2001.10213.x","volume":"1","author":"DS Batty Jr","year":"2001","unstructured":"Batty DS Jr, Swanson SJ, Kirk AD, Ko CW, Agodoa LY. Abbott KC: Hepatitis C virus seropositivity at the time of renal transplantation in the United States: Associated factors and patient survival. Am J Transplant. 2001;1:179\u201384.","journal-title":"Am J Transplant"},{"key":"149_CR3","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1086\/315869","volume":"182","author":"PM Schneeberger","year":"2000","unstructured":"Schneeberger PM, Keur I, van Loon AM, Mortier D, de Coul KO, van Haperen AV, et al. The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study. J Infect Dis. 2000;182:1291\u20139.","journal-title":"J Infect Dis"},{"key":"149_CR4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0272-6386(95)90100-0","volume":"25","author":"B Dussol","year":"1995","unstructured":"Dussol B, Berthezene P, Brunet P, Roubicek C. Berland Y: Hepatitis C virus infection among chronic dialysis patients in the south of France: a collaborative study. Am J Kidney Dis. 1995;25:399\u2013404.","journal-title":"Am J Kidney Dis"},{"key":"149_CR5","doi-asserted-by":"crossref","unstructured":"Anonymous. The current state of chronic dialysis treatment in Japan (as of December 31, 2000). Ther Aphersis Dial. 2003;7:3\u201335.","DOI":"10.1046\/j.1526-0968.2003.00001.x"},{"key":"149_CR6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/jhep.2002.34613","volume":"36","author":"F Fabrizi","year":"2002","unstructured":"Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology. 2002;36:3\u201310.","journal-title":"Hepatology"},{"key":"149_CR7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.0894-0959.2004.17339.x","volume":"17","author":"JI Tokars","year":"2004","unstructured":"Tokars JI, Finelli L, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2001. Semin Dial. 2004;17:310\u20139.","journal-title":"Semin Dial"},{"key":"149_CR8","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0272-6386(05)80017-4","volume":"37","author":"N Petrosillo","year":"2001","unstructured":"Petrosillo N, Gilli P, Serraino D, Dentico P, Mele A, Ragni P, et al. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis. 2001;37:1004\u201310.","journal-title":"Am J Kidney Dis"},{"key":"149_CR9","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/ki.1996.403","volume":"50","author":"D Marcelli","year":"1996","unstructured":"Marcelli D, Stannard D, Conte F, Held PJ, Locatelli F, Port FK. ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States. Kidney Int. 1996;50:1013\u20138.","journal-title":"Kidney Int"},{"key":"149_CR10","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1365-2036.2004.02290.x","volume":"20","author":"F Fabrizi","year":"2004","unstructured":"Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther. 2004;20:1271\u20137.","journal-title":"Aliment Pharmacol Ther"},{"key":"149_CR11","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1002\/hep.1840360707","volume":"36","author":"P Marcellin","year":"2002","unstructured":"Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology. 2002;36:S47\u201356.","journal-title":"Hepatology"},{"key":"149_CR12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/gast.2003.50018","volume":"124","author":"MG Ghany","year":"2003","unstructured":"Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology. 2003;124:97\u2013104.","journal-title":"Gastroenterology"},{"key":"149_CR13","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/ijc.21796","volume":"119","author":"R Suruki","year":"2006","unstructured":"Suruki R, Hayashi K, Kusumoto K, Uto H, Ido A, Tsubouchi H, et al. Alanine aminotransferase level as a predictor of hepatitis C virus-associated hepatocellular carcinoma incidence in a community-based population in Japan. Int J Cancer. 2006;119:192\u20135.","journal-title":"Int J Cancer"},{"key":"149_CR14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0272-6386(95)90617-7","volume":"25","author":"D Roth","year":"1995","unstructured":"Roth D. Hepatitis C virus: the nephrologist\u2019s view. Am J Kidney Dis. 1995;25:3\u201316.","journal-title":"Am J Kidney Dis"},{"key":"149_CR15","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/bmj.38050.593634.63","volume":"328","author":"HC Kim","year":"2004","unstructured":"Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. Br Med J. 2004;328:983\u20136.","journal-title":"Br Med J"},{"key":"149_CR16","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1023\/A:1026696721059","volume":"45","author":"N Furusyo","year":"2000","unstructured":"Furusyo N, Hayashi J, Kanamoto-Tanaka Y, Ariyama I, Etoh Y, Shigematsu M, et al. Liver damage in hemodialysis patients with hepatitis C virus viremia: a prospective 10-years study. Dig Dis Sci. 2000;45:2221\u20138.","journal-title":"Dig Dis Sci"},{"key":"149_CR17","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jcv.2005.09.010","volume":"35","author":"EP Lopes","year":"2006","unstructured":"Lopes EP, Gouveia EC, Albuquerque AC, Sette LH, Mello LA, Moreira RC, et al. Determination of the cut-off value of serum alanine aminotransferase in patients undergoing hemodialysis, to identify biochemical activity in patients with hepatitis C viremia. J Clin Virol. 2006;35:298\u2013302.","journal-title":"J Clin Virol"},{"key":"149_CR18","first-page":"518","volume":"38","author":"CT Wai","year":"2003","unstructured":"Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518\u201326.","journal-title":"Hepatology"},{"key":"149_CR19","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1111\/j.1572-0241.2005.51938.x","volume":"100","author":"KQ Hu","year":"2005","unstructured":"Hu KQ, Lee SM, Hu SX, Xia VW, Hillebrand DJ, Kyulo NL. Clinical presentation of chronic hepatitis C in patients with end-stage renal disease and on hemodialysis versus those with normal renal function. Am J Gastroenterol. 2005;100:2010\u20138.","journal-title":"Am J Gastroenterol"},{"key":"149_CR20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00535-009-0016-z","volume":"44","author":"S Kose","year":"2009","unstructured":"Kose S, Gurkan A, Akman F, Kelesoglu M, Uner U. Treatment of hepatitis C in hemodialysis patients using pegylated interferon \u03b1-2a in Turkey. J Gastroeterol. 2009;44:353\u20138.","journal-title":"J Gastroeterol"},{"key":"149_CR21","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/j.1572-0241.2003.07526.x","volume":"98","author":"MW Russo","year":"2003","unstructured":"Russo MW, Goldsweig C, Jacobson IM, Brown RS Jr. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol. 2003;98:1610\u20135.","journal-title":"Am J Gastroenterol"},{"key":"149_CR22","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/ndt\/16.5.1017","volume":"16","author":"F Degos","year":"2001","unstructured":"Degos F, Pol S, Chaix ML, Laffitte V, Buffet C, Bernard PH, et al. The tolerance and efficacy of interferon-\u03b1 in haemodialysis patients with HCV infection: a multicenter prospective study. Nephrol Dial Transplant. 2001;16:1017\u201323.","journal-title":"Nephrol Dial Transplant"},{"key":"149_CR23","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/gut.2007.120956","volume":"56","author":"M Omata","year":"2007","unstructured":"Omata M, Yoshida H, Toyota J, Tomita E, Nishiguchi S, Hayashi N, et al. Japanese C-Viral Hepatitis Network. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut. 2007;56:1747\u201353.","journal-title":"Gut"},{"key":"149_CR24","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/ndt\/gfn684","volume":"24","author":"DW Johnson","year":"2009","unstructured":"Johnson DW, Dent H, Yao Q, Tranaeus A, Huang CC, Han DS, et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia\u2013Pacific countries: analysis of registry data. Nephrol Dial Transplant. 2009;24:1598\u2013603.","journal-title":"Nephrol Dial Transplant"},{"key":"149_CR25","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/jmv.20389","volume":"76","author":"J Kumagai","year":"2005","unstructured":"Kumagai J, Komiya Y, Tanaka J, Katayama K, Tatsukawa Y, Yorioka N, et al. Hepatitis C virus infection in 2,744 hemodialysis patients followed regularly at nine centers in Hiroshima during November 1999 through February 2003. J Med Virol. 2005;76:498\u2013502.","journal-title":"J Med Virol"},{"key":"149_CR26","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1744-9987.2007.00523.x","volume":"11","author":"S Nakai","year":"2007","unstructured":"Nakai S, Masakane I, Akiba T, Iseki K, Watanabe Y, Itami N, et al. Overview of regular dialysis treatment in Japan (as of 31 December 2005). Ther Apher Dial. 2007;11:411\u201341.","journal-title":"Ther Apher Dial"},{"key":"149_CR27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000184118","volume":"45","author":"U Gafter","year":"1987","unstructured":"Gafter U, Bessler H, Malachi T, Zevin D, Djaldetti M, Levi J. Platelet count and thrombopoietic activity in patients with chronic renal failure. Nephron. 1987;45:207\u201310.","journal-title":"Nephron"},{"key":"149_CR28","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood.V97.4.915","volume":"97","author":"M Ando","year":"2001","unstructured":"Ando M, Iwamoto Y, Suda A, Tsuchiya K, Nihei H. New insights into the thrombopoietic status of patients on dialysis through the evaluation of megakaryocytopoiesis in bone marrow and of endogenous thrombopoietin levels. Blood. 2001;97:915\u201321.","journal-title":"Blood"},{"key":"149_CR29","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0272-6386(96)90134-1","volume":"28","author":"S Yamamoto","year":"1996","unstructured":"Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, et al. Heparin-induced thrombocytopenia in hemodialysis patients. Am J Kidney Dis. 1996;28:82\u20135.","journal-title":"Am J Kidney Dis"},{"key":"149_CR30","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3181\/00379727-149-38931","volume":"149","author":"SF Wallner","year":"1975","unstructured":"Wallner SF, Ward HP, Vautrin R, Alfrey AC, Mishell J. The anemia of chronic renal failure: in vitro response of bone marrow to erythropoietin. Proc Soc Exp Biol Med. 1975;149:939\u201344.","journal-title":"Proc Soc Exp Biol Med"},{"key":"149_CR31","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1681\/ASN.V11101896","volume":"11","author":"E Nakayama","year":"2000","unstructured":"Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol. 2000;11:1896\u2013902.","journal-title":"J Am Soc Nephrol"},{"key":"149_CR32","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","volume":"349","author":"T Poynard","year":"1997","unstructured":"Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825\u201332.","journal-title":"Lancet"},{"key":"149_CR33","doi-asserted-by":"crossref","first-page":"517","DOI":"10.7326\/0003-4819-132-7-200004040-00002","volume":"132","author":"Y Shiratori","year":"2000","unstructured":"Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000;132:517\u201324.","journal-title":"Ann Intern Med"},{"key":"149_CR34","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1386-6346(02)00108-0","volume":"24","author":"CW Chu","year":"2002","unstructured":"Chu CW, Hwang SJ, Lu RH, Lai CR, Luo JC, Wang YJ, et al. Clinical significance of the changes of platelet counts and serum thrombopoietin levels in chronic hepatitis C patients treated with different doses of consensus interferon. Hepatol Res. 2002;24:236.","journal-title":"Hepatol Res"},{"key":"149_CR35","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/ki.1981.69","volume":"19","author":"JD Kopple","year":"1981","unstructured":"Kopple JD, Mercurio K, Blumenkrantz MJ, Jones MR, Tallos J, Roberts C, et al. Daily requirement for pyridoxine supplements in chronic renal failure. Kidney Int. 1981;19:694\u2013704.","journal-title":"Kidney Int"},{"key":"149_CR36","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/clinchem\/32.11.2107a","volume":"32","author":"F Lente Van","year":"1986","unstructured":"Van Lente F, McHugh A, Pippenger CE. Carbamylation of apo-aspartate aminotransferase: a possible mechanism for enzyme inactivation in uremic patients. Clin Chem. 1986;32:2107\u20138.","journal-title":"Clin Chem"},{"key":"149_CR37","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/clinchem\/20.9.1213","volume":"20","author":"LG Warnock","year":"1974","unstructured":"Warnock LG, Stone WJ, Wagner C. Decreased aspartate aminotransferase (\u201cSGOT\u201d) activity in serum of uremic patients. Clin Chem. 1974;20:1213\u20136.","journal-title":"Clin Chem"},{"key":"149_CR38","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1111\/j.1572-0241.1999.01649.x","volume":"94","author":"RK Sterling","year":"1999","unstructured":"Sterling RK, Sanyal AJ, Luketic VA, Stravitz RT, King AL, Post AB, et al. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation. Am J Gastroenterol. 1999;94:3576\u201382.","journal-title":"Am J Gastroenterol"},{"key":"149_CR39","doi-asserted-by":"crossref","unstructured":"Contreras AM, Ruiz I, Polanco-Cruz G, Monte\u00f3n FJ, Celis A, V\u00e1zquez G, et al. End-stage renal disease and hepatitis C infection: comparison of alanine aminotransferase levels and liver histology in patients with and without renal damage. Ann Hepatol. 2007;6:48\u201354.","DOI":"10.1016\/S1665-2681(19)31953-2"},{"key":"149_CR40","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/hep.510260603","volume":"26","author":"C Puoti","year":"1997","unstructured":"Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology. 1997;26:1393\u20138.","journal-title":"Hepatology"},{"key":"149_CR41","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1872-034X.2007.00032.x","volume":"37","author":"I Shimizu","year":"2007","unstructured":"Shimizu I, Ito S. Protection of estrogens against the progression of chronic liver disease. Hepatol Res. 2007;37:239\u201347.","journal-title":"Hepatol Res"},{"key":"149_CR42","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1365-2893.2005.00667.x","volume":"13","author":"M Persico","year":"2006","unstructured":"Persico M, Perrotta S, Persico E, Terracciano L, Folgori A, Ruggeri L, et al. Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10\u00a0years. J Viral Hepat. 2006;13:290\u20136.","journal-title":"J Viral Hepat"},{"key":"149_CR43","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jhep.2005.04.008","volume":"43","author":"T Okanoue","year":"2005","unstructured":"Okanoue T, Makiyama A, Nakayama M, Sumida Y, Mitsuyoshi H, Nakajima T, et al. A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. J Hepatol. 2005;43:599\u2013605.","journal-title":"J Hepatol"},{"key":"149_CR44","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0016-5085(99)70135-6","volume":"116","author":"R Sobesky","year":"1999","unstructured":"Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology. 1999;116:378\u201386.","journal-title":"Gastroenterology"},{"key":"149_CR45","doi-asserted-by":"crossref","first-page":"174","DOI":"10.7326\/0003-4819-131-3-199908030-00003","volume":"131","author":"H Yoshida","year":"1999","unstructured":"Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med. 1999;131:174\u201381.","journal-title":"Ann Intern Med"},{"key":"149_CR46","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-2893.2000.00250.x","volume":"7","author":"A Kasahara","year":"2000","unstructured":"Kasahara A, Hayashi N, Mochizuki K, Hiramatsu N, Sasaki Y, Kakumu S, et al. Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy. The Osaka Liver Disease Study Group. J Viral Hepat. 2000;7:343\u201351.","journal-title":"J Viral Hepat"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-009-0149-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-009-0149-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-009-0149-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T10:03:43Z","timestamp":1634119423000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-009-0149-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,5]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["149"],"URL":"https:\/\/doi.org\/10.1007\/s00535-009-0149-0","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,5]]}}}